Efficacy and Safety of Amodiaquine and Amodiaquine-Artesunate
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00238017
Verified July 2005 by Charite University, Berlin, Germany. Recruitment status was: Active, not recruiting
The purpose of this study is to compare the efficacy and safety of two antimalarial drug regimes, namely amodiaquine versus amodiaquine-artesunate, in the treatment of children with uncomplicated malaria. Also, genetic host factors which might influence efficacy and/or safety will be examined.
Condition or disease
Drug: amodiaquine-artesunate versus amodiaquine
Malaria remains a major cause of morbidity and mortality among children in sub-Saharan Africa. Current malaria control largely consists of rapid treatment of patients. Amodiaquine-artesunate and other combinatory treatment regimes including amodiaquine are now being introduced as first-line antimalarial drugs in several African countries. However, data on the efficacy and safety of amodiaquine and amodiaquine-artesunate are scarce. In addition, there is evidence that common genetic host factors, e.g. sickle cell trait, may influence efficacy and safety of these drugs. To examine efficacy and safety of the named drugs as well as a potential influence of genetic host factors on these outcomes a randomized, double blind trial among 400 children with uncomplicated malaria is performed in northern Ghana.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
6 Months to 59 Months (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male and female outpatients aged 6 to 59 months
Body weight >5 kg
Uncomplicated Plasmodium falciparum malaria
Mono-infection with P. falciparum with an asexual parasite density between 2,000 to 200,000 parasites/μl
Axillary temperature ≥37.5°C
Ability to tolerate oral therapy
Informed consent by the legal representative of the subject
Residence in study area
Previous participation in this clinical trial
Haemoglobin <5 mg/dl
Mixed plasmodial infection
Danger signs (unable to drink; repeated vomiting; recent history of convulsions;lethargic or unconscious state; unable to stand up or to sit) and signs of severe malaria as defined by WHO.
Any other severe underlying disease (cardiac, renal, hepatic diseases, malnutrition, known HIV infection)
Concomitant disease masking assessment of response
History of allergy or intolerance against study medications